Dr. Jeffrey Alan Lieberman is a world-renowned psychiatrist and leading authority on schizophrenia and related psychoses. He currently serves as the Lawrence C. Kolb Professor and Chairman of Psychiatry at Columbia University College of Physicians and Surgeons and as Director of the New York State Psychiatric Institute. He also holds the Lieber Chair for Schizophrenia Research and serves as Psychiatrist in Chief at New York-Presbyterian Hospital, Columbia University Medical Center. Dr. Lieberman received his medical degree from the George Washington School of Medicine in 1975, with postgraduate training in psychiatry at St. Vincent's Hospital and the Medical Center of New York Medical College.
Dr. Lieberman's groundbreaking research has significantly advanced the understanding of the natural history and pathophysiology of schizophrenia and the pharmacology of antipsychotic drugs. He served as Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CATIE), the largest and longest independent study ever funded by the National Institute of Mental Health to examine existing pharmacotherapies for schizophrenia. His work has demonstrated that proven treatments like clozapine, long-acting injectable antipsychotics, and team-based multispecialty care can prevent the progression of schizophrenia when applied early. His extensive scholarly contributions include over 500 scientific publications and the authorship or editorship of twelve books including the widely used textbook Psychiatry.
Beyond his research contributions, Dr. Lieberman has been instrumental in shaping the field of psychiatric research through his leadership roles including service as President of the American Psychiatric Association from 2013 to 2014. He has received numerous prestigious awards including the Lieber Prize for Schizophrenia Research, the Adolph Meyer Award from the American Psychiatric Association, and the Research Award from the National Alliance on Mental Illness. As a member of the National Academy of Sciences Institute of Medicine, he continues to advocate for the implementation of evidence-based schizophrenia treatments that remain underutilized despite their proven benefits. His current work focuses on improving early intervention strategies and overcoming barriers to optimal schizophrenia care through the Recovery After an Initial Schizophrenic Episode program and continued advocacy efforts.
